Deep Track Capital, LP
Reported holdings as of Q2 2026, from 19 quarterly filings.
Holdings
| Security | Ticker | Value | Shares | Weight | Weight change | Held | Change |
|---|---|---|---|---|---|---|---|
| GUARDANT HEALTH INC | GH | $509.1M | 3,393,312 | +2.37pp | 13q | +1.6%+$8.3M | |
| IMMUNOVANT INC | IMVT | $359.9M | 9,341,151 | +0.56pp | 19q | -19.0%-$84.2M | |
| STRUCTURE THERAPEUTICS INC | GPCR | $254.4M | 4,740,072 | +0.33pp | 14q | +10.8%+$24.7M | |
| VAXCYTE INC | PCVX | $250.0M | 4,300,000 | -0.44pp | 6q | HELD | |
| ALNYLAM PHARMACEUTICALS INC | ALNY | $248.3M | 825,000 | - | new | NEW | |
| VERADERMICS INC | MANE | $245.9M | 2,000,000 | +3.06pp | 2q | +300.0%+$184.4M | |
| GENMAB A/S OPT | GMAB | $237.6M | 5,650,000 | +1.85pp | 2q | +54.2%+$83.6M | |
| TARSUS PHARMACEUTICALS INC | TARS | $230.8M | 3,666,768 | -0.76pp | 6q | +1.9%+$4.2M | |
| NUVALENT INC | NUVL | $220.2M | 1,783,322 | +0.90pp | 2q | +29.6%+$50.3M | |
| ALKERMES PLC | ALKS | $209.6M | 4,000,000 | +0.98pp | 3q | +11.4%+$21.5M | |
| OCULAR THERAPEUTIX INC | OCUL | $193.3M | 19,686,282 | +0.09pp | 11q | HELD | |
| BIOMARIN PHARMACEUTICAL INC | BMRN | $189.3M | 3,307,481 | +1.69pp | 4q | +187.6%+$123.5M | |
| NURIX THERAPEUTICS INC | NRIX | $187.7M | 7,736,455 | +1.13pp | 17q | +21.9%+$33.8M | |
| ORUKA THERAPEUTICS INC | ORKA | $183.3M | 1,926,000 | +1.04pp | 8q | -5.3%-$10.3M | |
| ALUMIS INC | ALMS | $178.6M | 6,348,558 | +0.16pp | 2q | -6.3%-$11.9M | |
| IONIS PHARMACEUTICALS INC | IONS | $174.4M | 2,200,000 | +0.15pp | 15q | +12.8%+$19.8M | |
| COMPASS PATHWAYS PLC | CMPS | $172.1M | 12,161,496 | +1.41pp | 6q | HELD | |
| VERA THERAPEUTICS INC | VERA | $171.6M | 4,000,000 | -0.20pp | 3q | -2.6%-$4.6M | |
| AXSOME THERAPEUTICS INC | AXSM | $171.3M | 700,000 | -0.54pp | 5q | -36.4%-$97.9M | |
| MOONLAKE IMMUNOTHERAPEUTICS | MLTX | $136.3M | 6,999,025 | +0.03pp | 3q | +9.2%+$11.5M | |
| HEMAB THERAPEUTICS HLDGS INC | $132.3M | 3,602,093 | - | new | NEW | ||
| TANGO THERAPEUTICS INC | TNGX | $131.3M | 4,200,000 | +0.97pp | 4q | +52.7%+$45.3M | |
| DEFINIUM THERAPEUTICS INC | DFTX | $129.4M | 2,750,000 | +0.96pp | 2q | -8.3%-$11.8M | |
| GRAIL INC | GRAL | $125.3M | 1,834,944 | +0.37pp | 3q | +6.5%+$7.7M | |
| BICARA THERAPEUTICS INC | BCAX | $121.7M | 4,100,000 | +0.45pp | 8q | +0.9%+$1.1M | |
| MAZE THERAPEUTICS INC | MAZE | $111.4M | 3,732,569 | -0.07pp | 6q | +7.3%+$7.6M | |
| CELLDEX THERAPEUTICS INC NEW | CLDX | $109.4M | 2,939,151 | +0.93pp | 7q | +128.9%+$61.6M | |
| LB PHARMACEUTICALS INC | LBRX | $108.8M | 3,352,804 | +0.23pp | 4q | HELD | |
| MBX BIOSCIENCES INC | MBX | $95.6M | 1,732,569 | +0.05pp | 8q | -37.2%-$56.6M | |
| GH RESEARCH PLC | GHRS | $89.6M | 3,333,334 | - | new | NEW | |
| COGENT BIOSCIENCES INC | COGT | $77.4M | 2,000,000 | +0.50pp | 3q | +100.0%+$38.7M | |
| ATAIBECKLEY INC | ATAI | $76.0M | 14,417,442 | +0.41pp | 2q | +20.1%+$12.7M | |
| UNITED THERAPEUTICS CORP DEL | UTHR | $67.0M | 123,616 | - | new | NEW | |
| AVALO THERAPEUTICS INC | AVTX | $66.7M | 3,610,000 | - | new | NEW | |
| VIRIDIAN THERAPEUTICS INC | VRDN | $66.0M | 3,592,740 | +0.52pp | 19q | +157.7%+$40.4M | |
| CYTOKINETICS INC | CYTK | $59.6M | 700,000 | -0.61pp | 9q | -49.1%-$57.4M | |
| ALTIMMUNE INC | ALT | $58.5M | 19,250,000 | - | new | NEW | |
| PERSONALIS INC | PSNL | $53.6M | 4,000,000 | +0.47pp | 2q | +33.3%+$13.4M | |
| ACLARIS THERAPEUTICS INC | ACRS | $49.4M | 9,345,000 | +0.15pp | 2q | HELD | |
| CORMEDIX INC | CRMD | $49.3M | 6,274,076 | +0.02pp | 4q | HELD | |
| GENEDX HOLDINGS CORP | WGS | $48.1M | 700,000 | - | new | NEW | |
| HARROW INC | HROW | $41.2M | 969,000 | - | new | NEW | |
| CORVUS PHARMACEUTICALS INC | CRVS | $37.2M | 2,491,939 | -0.05pp | 2q | HELD | |
| SOLID BIOSCIENCES INC | SLDB | $35.6M | 3,565,062 | +0.10pp | 2q | HELD | |
| BEAM THERAPEUTICS INC | BEAM | $34.3M | 1,000,000 | +0.18pp | 2q | +21.8%+$6.2M | |
| DYNE THERAPEUTICS INC | DYN | $33.3M | 1,500,000 | -0.11pp | 4q | -25.0%-$11.1M | |
| IMMIX BIOPHARMA INC | IMMX | $28.6M | 2,775,000 | - | new | NEW | |
| X4 PHARMACEUTICALS INC | XFOR | $27.5M | 5,878,757 | -0.03pp | 4q | -7.3%-$2.2M | |
| SHATTUCK LABS INC | STTK | $25.7M | 3,706,734 | - | new | NEW | |
| MANNKIND CORP | MNKD | $25.6M | 6,000,000 | - | new | NEW | |
| CENTURY THERAPEUTICS INC | IPSC | $23.2M | 9,462,645 | -0.01pp | 2q | HELD | |
| GENERATE BIOMEDICINES INC | GENB | $22.5M | 1,333,815 | - | new | NEW | |
| VERASTEM INC | VSTM | $21.9M | 5,740,850 | -0.18pp | 3q | HELD | |
| KURA ONCOLOGY INC | KURA | $21.7M | 1,978,565 | -0.04pp | 2q | -25.2%-$7.3M | |
| ENANTA PHARMACEUTICALS INC | ENTA | $21.1M | 1,444,167 | -0.10pp | 3q | -26.2%-$7.5M | |
| NEKTAR THERAPEUTICS | NKTR | $20.9M | 300,000 | - | new | NEW | |
| OLEMA PHARMACEUTICALS INC | OLMA | $18.8M | 1,500,000 | - | new | NEW | |
| KAILERA THERAPEUTICS INC | KLRA | $15.4M | 700,000 | - | new | NEW | |
| KARDIGAN INC | KARD | $14.3M | 600,000 | - | new | NEW | |
| ENLIVEN THERAPEUTICS INC | ELVN | $11.4M | 225,000 | - | new | NEW | |
| PROMIS NEUROSCIENCES INC | PMN | $11.0M | 835,655 | -0.01pp | 2q | HELD | |
| IMMUNOCORE HLDGS PLC | IMCR | $9.9M | 311,218 | -0.81pp | 7q | -83.9%-$51.5M | |
| XENCOR INC | XNCR | $9.6M | 593,551 | - | new | NEW | |
| CONTEXT THERAPEUTICS INC | CNTX | $4.1M | 7,419,355 | -0.26pp | 9q | HELD | |
| INVENTIVA SA | IVA | $3.0M | 800,000 | -0.07pp | 3q | -34.6%-$1.6M | |
| ALIGOS THERAPEUTICS INC | ALGS | $2.6M | 444,110 | -0.02pp | 8q | HELD |
By sector
Industry comes from the SIC code on each company's own SEC filings, which is self-reported and sometimes out of date. Derivative exposure is counted with the shares. Securities the SEC assigns no industry - funds, trusts, foreign issues - are shown as not classified rather than dropped.
| Sector | Value | Share |
|---|---|---|
| Biotech & Pharma | $5.8B | 83.7% |
| Healthcare Services | $736.0M | 10.7% |
| Not classified | $382.3M | 5.6% |
Quarter by quarter
| Quarter | Value | Positions | New | Added | Trimmed | Exited | Top 10 | Days to file |
|---|---|---|---|---|---|---|---|---|
| Q2 2026 | $6.9B | 66 | 18 | 21 | 14 | 15 | 40.3% | 45 |
| Q1 2026 | $6.1B | 63 | 16 | 23 | 14 | 8 | 53.6% | 45 |
| Q4 2025 | $5.6B | 55 | 17 | 17 | 15 | 18 | 60.1% | 44 |
| Q3 2025 | $3.6B | 56 | 12 | 12 | 20 | 21 | 52.6% | 45 |
| Q2 2025 | $3.1B | 65 | 7 | 18 | 19 | 11 | 52.4% | 45 |
| Q1 2025 | $3.1B | 69 | 16 | 25 | 8 | 9 | 53.1% | 45 |
| Q4 2024 | $2.7B | 62 | 15 | 17 | 20 | 22 | 52.0% | 45 |
| Q3 2024 | $3.2B | 69 | 11 | 20 | 22 | 10 | 41.1% | 45 |
| Q2 2024 | $3.4B | 68 | 11 | 22 | 18 | 8 | 41.7% | 45 |
| Q1 2024 | $3.5B | 65 | 19 | 14 | 16 | 12 | 38.4% | 45 |
| Q4 2023 | $3.0B | 58 | 13 | 15 | 16 | 18 | 41.3% | 45 |
| Q3 2023 | $2.6B | 63 | 16 | 18 | 12 | 8 | 45.9% | 45 |
| Q2 2023 | $2.2B | 55 | 14 | 13 | 13 | 16 | 51.1% | 68 |
| Q1 2023 | $2.4B | 57 | 16 | 12 | 14 | 17 | 47.1% | 45 |
| Q4 2022 | $2.4B | 58 | 13 | 16 | 21 | 16 | 47.9% | 45 |
| Q3 2022 | $2.2B | 61 | 17 | 12 | 21 | 7 | 46.1% | 45 |
| Q2 2022 | $1.5B | 51 | 6 | 22 | 11 | 6 | 48.9% | 43 |
| Q1 2022 | $1.6B | 51 | 10 | 27 | 9 | 12 | 50.4% | 46 |
| Q4 2021 | $1.4B | 53 | 0 | 0 | 0 | 0 | 42.7% | 45 |
Rows marked UNVERIFIED ID, PLACEHOLDER ID, TICKER AS ID or NON-CUSIP ID carry an identifier that is not a valid CUSIP. They are shown because the filer reported that money, but treat the security named with caution - hover the chip for what is wrong with it, and see the methodology.
Held counts consecutive filings in which this manager reported the position, and can reach further back than the quarters listed above: the tabs begin at Q4 2018 because earlier coverage is too sparse to describe a market, but tenure is counted over every filing we hold, some reaching to 2007. A position sold and later rebought starts again from one.
Weight change is the shift in this position's share of the whole book, in percentage points. It is the more useful column: when money flows into or out of a broad fund, almost every holding is bought or sold at once, so added and trimmed largely track flows. A weight that rose while the book shrank is a decision. Both compare with the previous quarter this filer reported, not the previous calendar quarter.